ArticleJACS Au2025
Engineering Lanthanide Ion-Labeled Aptamers for ICP-MS Profiling of Serum-Derived Extracellular Vesicles from Colorectal Cancer.
Article in JACS Au, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nucleic acid aptamers: new methods for selection, target validation, molecular diagnostics and therapeutics.Signal transduction and targeted therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Membrane proteins on extracellular vesicles (EVs) derived from clinical serum samples have emerged as promising biomarkers for cancer screening, early diagnosis and prognosis. However, high-throughput profiling of multiple EV proteins with high sensitivity and high selectivity is challenge for clinical applications. In this work, we synthesized a polymer capable of chelating a set of lanthanide ions labeled at the terminal of DNA aptamers. These lanthanide ions-labeled aptamers have high affinity for specific EV proteins. By utilizing ICP-MS, multiplex profiling was performed for four specific proteins on the surface of EVs with high sensitivity and selectivity for CRC diagnosis. Precise diagnosis of EVs from CRC patients were achieved with an accuracy of 89.9%, sensitivity of 86.3%, and specificity of 100%. This method features high sensitivity, low background, and rapid detection, demonstrating potential clinical application for in vitro diagnosis with blood samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.